1002-Targeting RAS-GTP Active State in KRAS Mutant Cancer

Paper Talk · May 20, 2026 · 26m

This research highlights the therapeutic potential of RAS(ON) multi-selective inhibitors for treating cholangiocarcinoma (CCA), a lethal bile duct cancer often driven by KRAS mutations. Using various preclinical models and patient data, the authors demonstrate that these inhibitors effectively block the active state of RAS proteins to trigger tumor regression and improved survival. The findings identify oncogenic flux—specifically through MYC expression and KRAS amplification—as a primary driver of drug resistance. Furthermore, the study reveals that combining these inhibitors with standard…